表纸
市场调查报告书

神经干细胞与前驱细胞产品的策略性开发

Strategic Development of Neural Stem & Progenitor Cell Products 2019

出版商 BIOINFORMANT WORLDWIDE, LLC 商品编码 227599
出版日期 内容资讯 英文 211 Pages
订单完成后即时交付
价格
Back to Top
神经干细胞与前驱细胞产品的策略性开发 Strategic Development of Neural Stem & Progenitor Cell Products 2019
出版日期: 2019年03月08日内容资讯: 英文 211 Pages
简介

本报告调查神经干细胞与前驱细胞产品市场,干细胞种类与概要、主要适应症的患病率及现行药物及疗法、不同开发阶段的临床研究与试验动向、主要企业档案等内容汇整如后。

第1章 报告概要

第2章 介绍

第3章 干细胞:概要

  • 胚胎干细胞(ES细胞)
  • 诱导性多功能干细胞(iPS细胞)
  • 从干细胞萃取出来特殊细胞的各种类型
  • 人类干细胞的各种类型
    • 人类胚胎干细胞(hESC)
    • 胚性生殖细胞(EG-Cell)
    • 胎生干细胞
    • 脐带干细胞
  • 成体干细胞
    • 造血干细胞(HSCs)
    • 间质干细胞(MSC)
    • 神经干细胞(NSC)
  • 各种来源培养的NSC基础特性

第4章 神经干细胞 (NSC):概要

  • NSC的来源
  • 各种来源的NSC基础特性
  • 神经退化性疾病的胎生干细胞移植。
  • 成体神经管细胞(aNSC)治疗
    • 现在的治疗环境

第5章 利用NSC有可能治疗之退化性疾病

  • 神经退化性疾病的传统治疗方法
  • 神经退化性疾病的NSC方法和传统方法
  • 理论和实践的一大差距
  • 利用NSC的细胞疗法的各种类型
  • 利用NSC移植而可能治疗的治疗效果
  • 最近的临床试验
  • 其他临床试验
  • 神经发育障碍和细胞疗法

第6章 脊髓损伤 (SCI) 和细胞疗法

  • 脊髓损伤的罹患率
  • 神经节(神经机能部位)和损伤的程度
  • 年度治疗费用、生涯治疗费:美国
  • 脊髓损伤的治疗药、治疗方法
  • CIRM的资金供给
  • 细胞疗法
  • 针对神经再生的SCI模式及其有效性
  • 临床试验清单

第7章 阿兹海默症

  • 罹患率
  • 美国65岁以上罹患人口预测
  • 美国治疗费:支付者分类
  • 现在可用的治疗药
  • CIRM的资金供给
  • 干细胞移植

第8章 帕金森氏症

  • 罹患率
  • CIRM的资金供给
  • 现在的治疗药
  • 细胞疗法可能性
  • 基因治疗

第9章 肌肉萎缩性侧索硬化症(ALS)

  • 罹患率
  • 对症疗法
  • CIRM的资金供给
  • 针对ALS的干细胞治疗企业
  • 细胞疗法

第10章 多发性硬化症(MS)

  • 罹患率
  • 治疗药
  • 神经干细胞的适用
  • 内在性神经性干细胞受到成长因子的刺激
  • CIRM的资金供给

第11章 中风

  • 罹患率
  • 现在可用治疗药
  • 干细胞治疗
  • 用于实验研究的各种干细胞
  • 进行中的临床试验
  • CIRM的资金供给

第12章 市场分析

  • 现在的干细胞环境
  • 主要临床的里程碑
  • 世界细胞疗法制品市场

第13章 主要企业档案

  • Asterias Biotherapeutics, Inc.
  • Athersys Inc.
  • Ncardia
  • Axol Bioscience.
  • BrainStorm Cell Therapeutics
  • Cellular Dynamics International, Inc.
  • Celther Polska
  • Cellartis AB
  • CellCure Neurosciences Ltd.
  • Celvive, Inc.
  • Merck Millipore
  • International Stem Cell Corporation
  • Kadimastem Ltd.
  • Living Cell Technologies Limited
  • MEDIPOST
  • Neuralstem Inc.
  • NeuroGeneration Inc.
  • Neurona Therapeutics Inc.
  • Ocata Therapeutics Inc.
  • Opexa Therapeutics, Inc.
  • ReNeuron Group PLC
  • RhinoCyte, Inc.
  • Roslin Cells Ltd.
  • SanBio, Inc.
  • Saneron CCEL Therapeutics Inc.
  • StemCells, Inc.
  • Stemedica Cell Technologies, Inc.
  • STEMCELL Technologies, Inc.
  • Talisman Therapeutics Ltd.
  • Xcelthera INC

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录

Neurogenesis is the process by which neurons are created. This process is most active during pre-natal development when neurogenesis is responsible for populating the growing brain. Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types include neurons, astrocytes, and oligodendrocytes. Neural progenitor cells (NPCs) are the progeny of stem cell division that normally undergo a limited number of replication cycles in vivo.

In 1992, Reynolds and Weiss were the first to isolate neural stem cells from the striatal tissue of adult mice brain tissue, including the subventricular zone, which is a neurogenic area. Since then, neural progenitor and stem cells have been isolated from various areas of the adult brain, including non-neurogenic areas like the spinal cord, and from other species, including humans. During the development of the nervous system, neural progenitor cells can either stay in the pool of proliferating undifferentiated cells or exit the cell cycle and differentiate. The past twenty years have seen great advances in neural stem cell research and applications.

NSCs can be regulated both in vitro and in vivo, which represent different commercial product opportunities. Neural stem cells have become of profound interest to the research community due to their potential to be used in drug discovery and delivery applications, as well as for tools of neural toxicology assessment. NSC transplantation also represents a ground-breaking approach for treating a range of chronic neurological diseases and acute CNS injuries, including Parkinson's, Alzheimer's and spinal cord injury, among other conditions.

Furthermore, neural stem and progenitor cells offer the potential to safely carry out pharmacology assessment for drugs designed to impact brain function or physiology. As tests on human cells become increasingly feasible, the potential grows for companies to develop disease-specific cell assays. As novel drug delivery agents, neural stem cells also show promise in killing gliomas and other cancers. To facilitate research resulting from these advances, a large and diverse market has emerged for neural stem cell products and services. One thriving component of the neural stem cell marketplace is the market for research reagents/supplies.

While the number of adult stem cell therapies entering clinical trials continues to expand, the development of neural stem cell therapies has been affected by barriers to entry that include patent restrictions, the complexity of neural stem cell applications, and burden of undertaking costly clinical trials. Despite these limitations, dozens of companies are now pursuing preclinical and clinical programs utilizing neural stem and progenitor cells as therapeutic products.

Pharmaceutical companies are demonstrating interest in neural stem and progenitor cells. Because of their plasticity, ability to develop into the main phenotypes of the nervous system, and unlimited capacity for self-renewal, NSCs have been proposed for use in a variety of pharmaceutical applications, including:

  • Neurotoxicity testing
  • Cellular therapies to treat CNS conditions
  • Neural tissue engineering and repair
  • Drug target validation and testing
  • Personalized medicine

Utilization of neural stem cell products by the pharmaceutical sector represents a thriving segment of the overall NSC marketplace. Of interest to this community is the use of neural stem cells to heal tissues that have a naturally limited capacity for renewal, including the human brain and spinal cord.

Development of new drugs is extremely costly and the success rate of bringing new compounds to the market is unpredictable. Therefore, it is crucial that pharmaceutical companies minimize late-stage product failures, including unexpected neurotoxic effects, that can arise when candidate drugs enter the clinical testing stages. It is desirable to test candidate drugs using in vitro assays of high human relevance as early as possible. Because neural stem cells have the potential to differentiate into nearly all the main phenotypes of the nervous system, they represent an ideal cell type from which to design such neural screening assays.

The concept of stem cells as a potential cure for neurodegenerative diseases is not new. While neural stem cells (NSCs) have been explored for more than two decades for use in treating neurodegenerative and neurodevelopmental diseases, recent progress with developing NSCs from human-induced pluripotent cells has accelerated interest in developing cell-based therapeutics to target neurodegenerative diseases. As safety and efficacy results having been obtained from preclinical and clinical tests performed in animal models, companies have moved onto human clinical trials using NSCs derived from different sources. For the first time in history, there are companies developing technologies to support autologous generation of neural stem cells by direct cell reprogramming.

Nearly one billion people in the aging population worldwide are affected by neurodegenerative diseases, there are no medications currently available to cure or stop the progression of these diseases. Available drugs can sometimes provide symptomatic relief, but they do not address the underlying disease, making alternative approaches badly needed. To date, researchers have successfully isolated, propagated, and characterized NSCs, and there are confirmed reports of neurogenesis of transplanted NSCs in the human brain. There has also been an upsurge in collaborative activities among pharmaceutical companies, research institutions, and start-up companies within the neurodegenerative market.

Growth of stem cell research has exploded over the past decades, and the market to for neural stem cell and progenitor cell products is also expanding. Claim this 211-page global strategic report to reveal the current and future needs of the NSC marketplace, outmaneuver your competition, and approach investors with specific and technical knowledge of the global market for neural stem cell and progenitor cell products.

Get immediate access to your product as an electronic (PDF) download with printing rights allowed.

Table of Contents

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.1. Executive Summary

2. INTRODUCTION

3. STEM CELLS: A BRIEF OVERIVEW

  • 3.1. Embryonic Stem Cells
  • 3.2. Induced Pluripotent Stem Cells
  • 3.3. Types of Specialized Cells Derived from Stem Cells
  • 3.4. Types of Stem Cells in the Human Body
    • 3.4.1. Human Embryonic Stem Cells
    • 3.4.2. Embryonic Germ Cells
    • 3.4.3. Fetal Stem Cells
    • 3.4.4. Umbilical Cord Stem Cells
  • 3.5. Adult Stem Cells
    • 3.5.1. Hematopoietic Stem Cells
    • 3.5.2. Mesenchymal Stem Cells
    • 3.5.3. Neural Stem Cells
      • 3.5.3.1. NSCs' Capacity to Migrate and Engraft
      • 3.5.3.2. Characterization of NSCs
      • 3.5.3.3. Major Three Neuronal Lineages from NSCs
  • 3.6. Characteristics of Different Types of Stem Cells

4. NEURAL STEM CELLS: AN OVERVIEW

  • 4.1. Sources of NSCs
  • 4.2. Basal Properties of NSCs Obtained from Different Sources
    • 4.2.1. BMSCs as a Sourse for NSC-Like Cells
    • 4.2.2. UCBSCs: Express Pro-Neural Genes and Neural Markers
    • 4.2.3. ESCs as a Source for NSCs
    • 4.2.4. iPSCs as a Source of NSCs
      • 4.2.4.1. Methods Used to Produce iPSCs
      • 4.2.4.2. Chemicals Used for Neural Differentiation of iPSCs
      • 4.2.4.3. Small-Molecule-Based Culture Protocols for Inducing hPSCs Differentiation
      • 4.2.4.4. Compounds Used for NSC Proliferation
      • 4.2.4.5. Synthetic Compounds Used to Induce NSC Differentiation into Neurons
      • 4.2.4.6. Natural Products Affecting NSC Survival, Proliferation, and Differentiation
  • 4.3. Fetal Stem Cell Transplantation for Neurodegenerative Diseases
  • 4.4. Adult Human Neural Stem Therapeutics
    • 4.4.1. Current Therapeutic Status of aNSCs

5. DEGENERATIVE DISEASES WITH POSSIBLE CURE USING NSCS

  • 5.1. Conventional Treatments for Neurodegenerative Diseases
  • 5.2. NSC-Based and Traditional Approaches for Neurodenerative Diseases
  • 5.3. The Wide Gap Between Theory and Practice in NSC Applications
  • 5.4. Types of NSCs Used for Cell Therapy Approaches
    • 5.4.1. Fetal and Adult-Derived NSCs
    • 5.4.2. NSCs from Pluripotent Stem Cells
  • 5.5. Possible Therapeutic Actions of Grafted NSCs in Neurodegenerative Diseases
  • 5.6. Most Recent Clinical Trials Using NSCs for Neurological Disorders
    • 5.6.1. Possible Outcome of Clinical Trials
  • 5.7. Other Clinical Trials Using NSCs for Neurodegenerative Diseases
  • 5.8. Neurodevelopmental Disorders and Cell Therapy
    • 5.8.1. Clinical Trials for Neurodevelopmental Disorders

6. SPINAL CORD INJURY AND CELL THERAPY

  • 6.1. Incidence of Spinal Cord Injury
  • 6.2. Neurological Level and Extent of Lesion in Spinal Cord Injuries
  • 6.3. Annual and Lifetime Cost of Treating SCI Patients in the US
  • 6.4. Medications and Other Treatments for Spinal Cord Injury
  • 6.5. CIRM Funding for Spinal Cord Injury
  • 6.6. Cell Therapy for Spinal Cord Injury
    • 6.6.1. Studies in Animal Models of Cell Therapy for SCI
      • 6.6.1.1. Preclinical Trials Using MSCs for SCI
      • 6.6.1.2. Preclinical Trials Using NPCs for SCI
      • 6.6.1.3. Preclinical Studies Using Olfactory Ensheathing Cells for SCI
      • 6.6.1.4. Preclinical Studies Using SCs for SCI
  • 6.7. SCI Models and Effectiveness of Neuronal Regeneration
  • 6.8. Clinical Trials Using Stem Cells for Spinal Cord Injury

7. ALZHEIMER'S DISEASE

  • 7.1. Incidence of Alzheimer's Disease
  • 7.2. Projected Number of People Aged 65 and Older with Alzheimer's Disease in the US
  • 7.3. Cost of Care by Payment Source for US Alzheimer's Patients
    • 7.3.1. Total Cost of Health Care, Long-Term Care, and Hospice for US AD Patients
  • 7.4. Currently Available Medications for Alzheimer's Disease
  • 7.5. CIRM Funding for Alzheimer's Research
  • 7.6. Transplantation of Stem Cells for AD
    • 7.6.1. Gene Therapy for AD

8. PARKINSON'S DISEASE

  • 8.1. Incidence of Parkinson's Disease
  • 8.2. CIRM Grants Targeting Parkinson's Disease
  • 8.3. Current Medications for PD
  • 8.4. Potential for Cell Therapy in Parkinson's Disease
  • 8.5. Gene Therapy for PD

9. AMYOTROPHIC LATERAL SCLEROSIS

  • 9.1. Incidence of ALS
  • 9.2. Symptomatic Treatments in ALS Patients
  • 9.3. CIRM Grants Targeting ALS
  • 9.4. Companies Focusing on Stem Cell Therapy for ALS
  • 9.5. Cell Therapy for ALS

10. MULTIPLE SCLEROSIS

  • 10.1. Incidence of MS
  • 10.2. Medications for MS
  • 10.3. Neural Stem Cells' Application in Multiple Sclerosis
  • 10.4. Stimulation of Endogenous NSCs with Growth Factors for MS Treatment
  • 10.5. CIRM Grants Targeting MS

11. STROKE

  • 11.1. Incidence of Stroke
  • 11.2. Currently Available Medication for Stroke
  • 11.3. Stem Cell-Based Therapies for Stroke
  • 11.4. Various Stem Cell Types Used in Stroke Experimental Studies
  • 11.5. Ongoing Clinical Trials for Stroke Using Stem Cells
  • 11.6. CIRM Grants Targeting Stroke

12. MARKET ANALYSIS

  • 12.1. Current Stem Cell Landscape
    • 12.1.1. Number of Stem Cell Product Candidates
    • 12.1.2. Commercial Stem Cell Therapy Development by Geography
    • 12.1.3. Commercially Attractive Therapeutic Areas
    • 12.1.4. Major Companies Investing in Stem Cell Industry
    • 12.1.5. Venturing of Big Pharma into Stem Cell Therapy Sector
  • 12.3. Major Clinical Milestones in Cell Therapy Sector
    • 12.3.1. TiGenics' Cx601
    • 12.3.2. Mesoblast Ltd. and JCR Pharmaceuticals Co., Ltd.
    • 12.3.3. Chiesi's Holocar
    • 12.3.4. ReNeuron's Retinitis Pigmentosa Cell Therapy Candidate
    • 12.3.5. Orphan Drug Designation to Pluristem's PLX-PAD Cells
  • 12.4. Major Anticipated Cell Therapy Clinical Data Events
  • 12.5. Global Market for Cell Therapy Products
    • 12.5.1. Global Market for Neural Stem Cells

13. SELECTED COMPANY PROFILES

  • 13.1. Asterias Biotherapeutics, Inc.
    • 13.1.1. AST-OPC1
  • 13.2. Athersys Inc
    • 13.2.1. MultiStem Programs
    • 13.2.2. Ischemic Stroke
    • 13.2.3. Clinical Programs (Stroke Phase II)
  • 13.3. Ncardia (Formed by Merger of Axiogenesis AG / Pluriomics)
    • 13.3.1. Peri.4U - Human iPS Cell-Derived Peripheral Neurons
    • 13.3.2. Dopa.4U - Human iPS Cell-Derived Dopaminergic Neurons
    • 13.3.3. CNS.4U-Human iPS Cell-Derived Central Nervous System Cells
    • 13.3.4. Astro.4U-Human iPS Cell-Derived Astrocytes
  • 13.4. Axol Bioscience.
    • 13.4.1. Cortical Neural Stem Cells
    • 13.4.2. Cerebral Cortical Neurons
    • 13.4.3. Sensory Neural Progenitors
    • 13.4.4. Motor Neuron Progenitors
    • 13.4.5. iPSC-derived Microglia
  • 13.5. BrainStorm Cell Therapeutics
    • 13.5.1. NurOwn in the Clinic
  • 13.6. Cellular Dynamics International, Inc.
    • 13.6.1. iCell Neurons
    • 13.6.2. iCell Astrocytes
    • 13.6.3. iCell DopaNeurons
  • 13.7. Celther Polska
    • 13.7.1. Cell Lines
  • 13.8. Cellartis AB
    • 13.8.1. hESC-Derived Mesenchymal Progenitor Cells
    • 13.8.2. Human Neural Stem Cells
    • 13.8.3. Culture System for iPSC
  • 13.9. CellCure Neurosciences Ltd.
    • 13.9.1. Technology
    • 13.9.2. New Candidate Treatment for Retinal Diseases
  • 13.10. Celvive, Inc.
    • 13.10.1. Spinal Cord Injury
    • 13.10.2. Research and Development
  • 13.11. Merck Millipore
    • 13.11.1. Human Neural Stem Lines
  • 13.12. International Stem Cell Corporation
    • 13.12.1. Neural Stem Cells
  • 13.13. Kadimastem Ltd.
    • 13.13.1. Drug Discovery for Neural Diseases
    • 13.13.2. Human Oligodendrocyte Drug-Screening Assays
  • 13.14. Living Cell Technologies Limited
    • 13.14.1. NTCELL
  • 13.15. MEDIPOST
    • 13.15.1. NEUROSTEM
  • 13.16. Neuralstem Inc.
    • 13.16.1. NSI-566 for ALS
    • 13.16.2. NSI-566 for SCI
    • 13.16.3. NSI-566 for Ischemic Stroke
  • 13.17. NeuroGeneration Inc.
    • 13.17.1. Drug Discovery
    • 13.17.2. Biotherapeutics
  • 13.18. Neurona Therapeutics Inc.
    • 13.18.1. Technology
  • 13.19. Ocata Therapeutics Inc. (Acquired by Astellas Pharma for $379M in Nov. 2015)
    • 13.19.1. Focus on Neuroscience
  • 13.20. Opexa Therapeutics, Inc
    • 13.20.1. Tcelna
    • 13.20.2. OPX-212
    • 13.20.3. Abili-T Clinical Study
  • 13.21. ReNeuron Group PLC
    • 13.21.1. Products and Technologies
    • 13.21.3. Human Retinal Progenitor Cells
    • 13.21.4. Exosome Platform
    • 13.21.5. ReNcell Products
  • 13.22. RhinoCyte, Inc.
    • 13.22.1. Research
  • 13.23. Roslin Cells Ltd.
    • 13.23.1. Custom iPSC Generation
  • 13.24. SanBio, Inc.
    • 13.24.1. SB623
    • 13.24.2. SB618
  • 13.25. Saneron CCEL Therapeutics Inc.
    • 13.25.1. U-CORD-CELL Program
    • 13.25.2. SERT-CELL Program
  • 13.26. StemCells, Inc.
    • 13.26.1. Clinical Programs
    • 13.26.2. HuCNS-SC (human neural stem cells)
    • 13.26.3. Proof of Concept
    • 13.26.4. Proof of Safety and Initial Efficacy
    • 13.26.5. Spinal Cord Injury
    • 13.26.6. Age-Related Macular Degeneration
    • 13.26.7. Pelizaeus-Merzbacher Disease
    • 13.26.8. Neuronal Ceroid Lipofuscinosis
  • 13.27. Stemedica Cell Technologies, Inc.
    • 13.27.1. Technology
    • 13.27.2. Products
      • 13.27.2.1. Stemedyne-MSC
      • 13.27.2.2. Stemedyne-NSC
      • 13.27.2.3. Stemedyne-RPE
  • 13.28. STEMCELL Technologies, Inc.
    • 13.28.1. Cell Culture Media for NSC and Progenitor Cells
  • 13.29. Talisman Therapeutics Ltd.
  • 13.30. Xcelthera INC
    • 13.30.1. Technology Platforms
    • 13.30.2. PluriXcel-DCS Technology
    • 13.30.3. PluriXcel-SMI Technology
    • 13.30.4. PlunXcel-SMI Neuron Technology
    • 13.30.5. PluriXcel-SMI Heart Technology
    • 13.30.6. Products
      • 13.30.6.1. Xcel-hNuP
      • 13.30.6.2. Xcel-hNu
      • 13.30.6.3. Xcel-hCardP
      • 13.30.6.4. Xcel-hcM

APPENDIX

  • Appendix 1: Globally Distributed Stem Cell and Cell Therapy Companies

INDEX OF FIGURES

  • FIGURE 3.4: Types of Specialized Cells Derived from Stem Cells
  • FIGURE 3.5: Major Three Neural Lineages from Neural Stem Cells
  • FIGURE 3.6: Structure of a Neuron
  • FIGURE 3.7: Structure of Astrocytes
  • FIGURE 3.8: Structure of Oligodendrocytes
  • FIGURE 5.1: Approaches for Neural Stem Replacement for Neurodevelopmental Disorders
  • FIGURE 6.1: Causes of Spinal Cord Injuries
  • FIGURE 6.2: Neurological Level and Extent of Lesion in Spinal Cord Injuries
  • FIGURE 6.3: Types and Share of Different Types of Stem Cells Used in SCI Clinical Trials
  • FIGURE 7.1: Ages of People with Alzheimer's Disease in the US
  • FIGURE 7.2: Number of People Aged 65 and Older with Alzheimer's Disease in the US, 2050
  • FIGURE 7.3: Cost of Care by Payment Source for US Alzheimer's Patients
  • FIGURE 12.1: Stem Cell Therapy Development
  • FIGURE 12.2: Number of Therapies by Phase
  • FIGURE 12.3: Global Market for NSCs, Through 2023

INDEX OF TABLES

  • TABLE 3.1: NSCs, NPCs, and their Lineage-Specific Markers
  • TABLE 3.2: Characteristics of Different Types of Stem Cells
  • TABLE 4.1: Sources of NSCs and Advantages and Disadvantages in their Applications
  • TABLE 4.2: Different Types of NSCs and their Basal Properties
  • TABLE 4.3: Advantages and Disadvantages of iPSCs Utilization
  • TABLE 4.4: Methods Used to Generate iPSCs
  • TABLE 4.5: Chemicals Used for Neural Differentiation of iPSCs
  • TABLE 4.6 Small-Molecule-Based Culture Protocols for Inducing hPSCs Differentiation
  • TABLE 4.7: Compounds Used in Neural Stem Cell Research
  • TABLE 4.8: Synthetic Compounds Used to Induce NSC Differentiation into Neurons
  • TABLE 4.9: Natural Products Known to Affect NSC Survival, Proliferation, and Differentiation
  • TABLE 4.10: Ongoing Clinical Trials of Fetal Stem Cell Transplantation for Neurological Diseases
  • TABLE 4.11: The Various Methods of Isolation, Culture, and Expansion of aNSCs
  • TABLE 4.12: Preclinical Results (Rat) of aNSCs against Neurodegenerative Diseases
  • TABLE 4.13: Trial ID & Title of Clinical Trials of aNSCs against Neurodegenerative Diseases
  • TABLE 4.14: Trial ID, Cell Source, Location, and Phases of Current Clinical Trials of aNSCs
  • TABLE 5.1: Conventional Treatments for Alzheimer's, Parkinson's, and Huntington's Diseases
  • TABLE 5.2: NSC-Based Approaches for Neurodegenerative Diseases
  • TABLE 5.3: Some Recent Clinical Trials Using NSCs for Treating Neurological Diseases
  • TABLE 5.4: NCT Numbers & Titles of Clinical Trials Using NSCs for Neurodegenerative Diseases
  • TABLE 5.5: Status of Different Clinical Trials Using NSCs for Neurodegenerative Diseases
  • TABLE 5.6: NCT Number and Titles of Clinical Trials for Neurodevelopmental Disorders
  • TABLE 5.7: Status of Clinical Trials Using NSCs for Neurodevelopmental Diseases
  • TABLE 6.1: Annual and Lifetime Cost of Treating SCI Patients in the US
  • TABLE 6.2: Oral Medications and Other Treatment Options for SCI
  • TABLE 6.3: CIRM's Grants Targeting Spinal Cord Injury
  • TABLE 6.4: Genes Used for Engineering Cells
  • TABLE 6.5: Preclinical SPI Trials Using iPSCs/ESCs for SCI
  • TABLE 6.6: Preclinical Spinal Cord Injury Trials Using Mesenchymal Stromal Cells
  • TABLE 6.7: Preclinical Spinal Cord Injury Trials Using NSCs/NPCs
  • TABLE 6.8: Preclinical SCI Trials Using Olfactory Ensheathing Cells
  • TABLE 6.9: Preclinical SCI Trials Using Schwann Cells
  • TABLE 6.10: SCI Models and Effectiveness of Neuronal Regeneration
  • TABLE 6.11: Clinical Trials in Different Countries for SCI
  • TABLE 7.1: Total Cost of Health Care, Long-Term Care, and Hospice for US Alzheimer's Patients
  • TABLE 7.2: Currently Available Pharmacologic Therapies for Alzheimer's Disease
  • TABLE 7.3: CIRM Funding for Alzheimer's Research
  • TABLE 7.4: Stem Cell Therapy for AD in Mice Models
  • TABLE 7.5: Gene Therapy for AD
  • TABLE 8.1: CIRM Grants Targeting Parkinson's Disease
  • TABLE 8.2: Medications for Motor Symptoms in PD
  • TABLE 8.3: Advantages and Disadvantages of Stem Cell Types Used in PD
  • TABLE 8.4: Approaches Used in Current Gene Therapy Clinical Trials for PD
  • TABLE 9.1: Symptomatic Treatments in ALS Patients
  • TABLE 9.2: CIRM Grants Targeting ALS
  • TABLE 9.4: Companies Focusing on Various Strategies for ALS
  • TABLE 9.6: Examples of Clinical Trials for Amyotrophic Lateral Sclerosis
  • TABLE 10.1: Currently Available Medications for MS
  • TABLE 10.2: Available Studies Related to the Use of NSCs for Multiple Sclerosis
  • TABLE 10.3: Growth Factors and Secreted Molecules Used for Stimulating Endogenous NSCs
  • TABLE 10.4: CIRM Grants Targeting MS
  • TABLE 11.1: An Overview of NSC Transplantation Experiments in Ischemic Stroke Models
  • TABLE 11.2: Representative Experimental Studies of Various Cell-Based Therapies for Stroke
  • TABLE 11.3: Ongoing Clinical Trials of Cell-Based Therapies for Stroke
  • TABLE 11.4: CIRM Grants Targeting Stroke
  • TABLE 12.1: Number of Therapies by Phase
  • TABLE 12.2: Stem Cell Product Candidates in Various Stages by Therapeutic Area
  • TABLE 12.3: Stem Cell Therapies in Phase III and Pre-Registration
  • TABLE 12.4: Companies with Active Stem Cell Therapy Pipelines
  • TABLE 12.5: Big Pharma's Involvement in Stem Cell Sector
  • TABLE 12.6: Major Anticipated Cell Therapy Clinical Data Events
  • TABLE 12.7: Global Market for Neural Stem Cells (NSCs), Through 2023
  • TABLE 13.1: Neuralstem Inc.'s Cell Therapy Products in Development
  • TABLE 13.2: Opexa's Product Pipeline
  • TABLE 13.3: ReNeuron's Pipeline Candidates
  • TABLE 13.4: SanBio's Product Pipeline
  • TABLE 13.5: STEMCELL Technologies' Cell Culture Media for NSCs
  • TABLE App. 1.1: Stem Cell and Cell Therapy Companies
Back to Top